Interventions for Tuberculosis Control and Elimination 2002

310. Yeager RL, Munroe WGC, Dessau FI. Pyrazinamide (Aldinamide) in the treatment
of pulmonary tuberculosis. Am Rev Tuberc 1952; 65: 523-46.
311. Kataria YP. Observations on human infection with Mycobacterium bovis.
Tubercle 1969; 50: 14-21.
312. Ellard GA, Humphries MJ, Gabriel M, Theoh R. Penetration of pyrazinamide
into the cerebrospinal fluid in tuberculous meningitis. BMJ 1987; 294: 284-5.
313. Donald PR, Seifart H. Cerebrospinal fluid pyrazinamide concentrations in children
with tuberculous meningitis. Pediatr Infect Dis 1988; 7: 469-71.
314. Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man.
Tubercle 1969; 50: 144-58.
315. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE.
Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with
antacids. Pharmacotherapy 1998; 18: 1205-11.
316. Schwartz WS, Moyer RE. The chemotherapy of pulmonary tuberculosis with
pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic
acid, or isoniazid. Am Rev Tuberc 1954; 70: 413-23.
317. McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune RM, Jr,
Tompsett R.
319-33.
Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 1954; 69:
318. Ferebee SH, Mount FW. Chemotherapy of tuberculosis, progress and promise.
Publ Health Rep 1957; 72: 412-20.
319. Mount FW, Wunderlich GS, Murray SJ, Ferebee SH. Hepatic toxicity of pyrazinamide
used with isoniazid in tuberculous patients. A United States Public Health
Service Tuberculosis Therapy Trial. Am Rev Respir Dis 1959; 80: 371-87.
320. van der Kooi K, Mottet JJ, Regamey C. Isoniazid is not always the cause of
hepatitis during treatment of tuberculosis.
1994; 19: 988-9.
(Correspondence). Clin Infect Dis
321. Türktas H, Ünsal M, Tülek N, Örüç O. Hepatotoxicity of antituberculosis therapy
(rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Dis 1994; 75: 58-60.
Tubercle Lung
322. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs
AK, McIntyre N. Anti-tuberculosis medications and the liver: dangers and recommendations
in management. Eur Respir J 1995; 8: 1384-8.
323. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis
drugs: observations in routine treatment. Tubercle Lung Dis 1996; 77: 37-42.
324. Philipps S. Pyrazinamide-isoniazid: its apparent influence on the reactivation rate
in pulmonary tuberculosis. Am Rev Respir Dis 1967; 95: 503-5.
325. Jenner PJ, Ellard GA, Allan WGL, Singh D, Girling DJ, Nunn AJ. Serum uric
acid concentrations and arthralgia among patients treated with pyrazinamide-containing
regimens in Hong Kong and Singapore. Tubercle 1981; 62: 175-9.
190